secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001104659-24-033491
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport FY 2023 revenue $233.3M (-2% YoY); net loss $99.6M; guides FY 2024 $242-252M
--------------------------------------------------------------------------------

- Q4 revenue $57.3M (-5% YoY); FY revenue $233.3M (-2% YoY). Services grew 8% but product fell 14%.
- Net loss for FY $99.6M includes $49.6M goodwill impairment; adjusted EBITDA negative $8.3M vs positive $13.9M prior year.
- Commercial Cell & Gene therapy revenue up 33% YoY; BioStorage/BioServices up 45%; record 675 clinical trials supported.
- FY 2024 revenue guidance $242-252M; expects progressive growth.
- Cash, equivalents & short-term investments $456.8M; $36M remaining under $100M repurchase program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465924033491/0001104659-24-033491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465924033491/tm248611d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer